Comparative Pharmacology
Head-to-head clinical analysis: FLAC versus LOTEPREDNOL ETABONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAC versus LOTEPREDNOL ETABONATE.
FLAC vs LOTEPREDNOL ETABONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLAC (Fluorouracil) is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is converted to active metabolites (FdUMP, FUTP) that disrupt RNA function and DNA replication.
Corticosteroid with high glucocorticoid receptor affinity; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Adults: 40 mg orally twice daily.
0.5% ophthalmic suspension: 1-2 drops into affected eye(s) four times daily. In severe cases, may be increased to 1-2 drops every hour during the first week, then taper.
None Documented
None Documented
2-4 hours; prolonged in renal impairment (up to 12 hours)
Terminal elimination half-life is 2.2-4.3 hours; clinical context: supports twice-daily dosing in ophthalmic use, with minimal systemic accumulation.
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%
Primarily hepatic metabolism; metabolites excreted in urine (approximately 80% as inactive metabolites) and feces (15-20%). Less than 1% excreted unchanged in urine.
Category C
Category C
Corticosteroid
Corticosteroid